<DOC>
	<DOC>NCT02367794</DOC>
	<brief_summary>This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy- naive participants with Stage IV squamous NSCLC.</brief_summary>
	<brief_title>A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Participants With Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) [IMpower 131]</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Histologically or cytologically confirmed, treatmentna√Øve Stage IV squamous NSCLC Previously obtained archival tumor tissue or tissue obtained from biopsy at screening Measurable disease as defined by RECIST v1.1 Adequate hematologic and end organ function Active or untreated central nervous system (CNS) metastasis Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome Pregnant or lactating women History of autoimmune disease History of idiopathic pulmonary fibrosis, organizing pneumonia, druginduced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest Computed Tomography (CT) scan, History of radiation pneumonitis in the radiation field (fibrosis) is permitted Positive test for Human Immunodeficiency Virus (HIV) Active hepatitis B or hepatitis C Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies, antiprogrammed death1 (antiPD1), and antiprogrammed deathligand 1 (antiPDL1) therapeutic antibody Severe infection within 4 weeks prior to randomization Significant history of cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>